Objective: To compare angiotensin-converting enzyme (ACE) inhibitor use in patients with type 2 diabetes at 1 year and 3 years after guidelines were published. Study Design: Retrospective database ...
St. Louis, Mo. (June 9, 2014) – The prominent role a single enzyme plays in cancer imaging has eluded researchers for years, but not anymore. This discovery could pave new avenues in nuclear medicine.
Enzyme inhibitors play a pivotal role in pharmaceutical and nutraceutical industries. The primary understanding of the action of inhibitors helps pharmacologists during the design process for ...
3D structure of a melanoma cell derived by ion abrasion scanning electron microscopy [National Cancer Institute (NCI). Image created by Sriram Subramaniam, NCI] Researchers at Sanford Burnham Prebys ...
Angiotensin-converting enzyme inhibitors and angiotensin receptor blockers are antihypertensive medicines used to treat high blood pressure. While the enzyme inhibitors work by reducing the level of ...
Molecular Tumor Board–Assisted Care in an Advanced Cancer Population: Results of a Phase II Clinical Trial The development of the selective RET inhibitors selpercatinib and pralsetinib has ...
New signals of a potential additive benefit from the nonsteroidal mineralocorticoid antagonist finerenone (Kerendia) and a sodium-glucose cotransporter 2 (SGLT2) inhibitor in patients with type 2 ...
Everyday Health on MSN
SGLT2 inhibitors and IgAN: Can this diabetes drug delay kidney decline?
Explore the potential of SGLT2 inhibitors for IgAN. Learn how these diabetes drugs slow kidney damage progression when added to standard treatment.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results